
WHO says training 49,000 health workers for Pakistan's first HPV vaccination drive in September
HPV is a very common virus that can cause cancers later in life, according to the Centers for Disease Control and Prevention (CDC). About 13 million people, including teens, become infected with HPV each year. Medical experts recommend protecting children from these cancers through the HPV vaccine.
In its press release, the WHO said cervical cancer ranks as the third most frequent cancer among Pakistani women. It said the country has a female population of 73.8 million aged 15 years and older at risk of the virus and reports 5,000 new cases of cervical cancer in women annually. The global health body said almost 3,200 of these 5,000 cases, roughly 64 percent, die from the disease.
'The campaign will be a historic milestone to prevent cervical cancer in the country, targeting for the first time 13 million girls aged 9 to 14 years across Punjab, Sindh, Islamabad Capital Territory and Pakistan-administered Kashmir,' the statement said.
The WHO said that with funding support from Gavi, the Vaccine Alliance, the training sessions for health workers will be conducted until the end of August and would focus on microplanning and essential skills for vaccinators, doctors, social mobilizers and data entry operators.
It said WHO's support for the drive includes technical guidance for conceptualization, planning, data analysis, readiness assessments and capacity development in close collaboration with partners, the Pakistan Federal Directorate of Immunization (FDI) and its Expanded Programme on Immunization (EPI) at the federal and provincial levels.
'This HPV vaccination campaign is more than just a public health intervention; it is an investment in the health and potential of our daughters,' Dr. Soofia Yunus, director-general, FDI, said. 'By embracing this vaccine, Pakistan is taking a big step to protect its future from cervical cancer.'
It said the vaccination campaign aligns with the World Health Assembly's Global Strategy for cervical cancer elimination. The strategy aims that by 2030, 90 percent of girls are fully vaccinated with the HPV vaccine by 15 years of age, 70 percent of women are screened, and 90 percent of women with pre-cancer or invasive cancer receive treatment.
The global health body said Pakistan's mortality rate for cervical cancer can primarily be attributed to delayed diagnoses and limited access to screening programs. The WHO said a recent study it conducted across 18 health care facilities in Pakistan from 2021-2023, 1,580 cases of cervical cancer were documented, indicating a significant underestimation of the disease burden due to low screening rates and the lack of a national cervical cancer registry.
'Modelling data indicates that, in the absence of vaccination, the cervical cancer disease burden in Pakistan will increase markedly by at least three-fold over the next seven decades,' the statement said.
WHO said the HPV vaccine's phased introduction will pave the way for its eventual rollout in other Pakistani provinces and areas, such as the northwestern Khyber Pakhtunkhwa in 2026, and Balochistan and Gilgit-Baltistan in 2027.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Saudi Gazette
7 hours ago
- Saudi Gazette
WHO designates Jeddah and Madinah among 16 'Healthy Cities'
Saudi Gazette report RIYADH — The World Health Organization (WHO) has designated 16 cities as 'Healthy Cities' and two Saudi cities found a place among them, according to the Ministry of Health. Jeddah and Madinah stand out as the first cities in the Middle East with populations of two million to receive the accreditation, marking a key milestone in the ministry's Healthy Cities Program and its ongoing efforts to enhance quality of life. The accomplishment reflects successful collaboration among government and community stakeholders, through the application of more than 80 international evaluation criteria across nine core domains spanning health, development, and sustainability. The ministry noted that the national health system continues to strengthen its global standing through a series of significant achievements in scientific research and international recognition. The Kingdom has also made notable advances in medical research and innovation. A study conducted by King Faisal Specialist Hospital and Research Centre (KFSHRC) on robotic liver transplantation was named one of the top 10 most influential research papers of 2024 by the American Society of Transplantation. In addition, seven Saudi hospitals were included in Brand Finance's Global Top 250 Hospitals 2025 report, highlighting the Kingdom's strong healthcare infrastructure, international competitiveness, and commitment to high-quality patient care. These accomplishments are closely aligned with the objectives of Saudi Vision 2030 — particularly the 'A Vibrant Society' and 'A Thriving Economy' pillars, to enhance quality of life and support innovation and scientific advancement. Together, these milestones reflect the integrated efforts of the national health system and various sectors, reinforcing the Kingdom's position as a regional hub and global destination for advanced healthcare.


Al Arabiya
19 hours ago
- Al Arabiya
One in four US adults with diabetes used GLP-1 injections in 2024: CDC
More than one in four US adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the US Centers for Disease Control and Prevention said on Thursday. The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions. Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3 percent, reflecting the more significant disease burden in this group, the report said. A quarter or 25.3 percent of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8 percent among those 65 and older. The data are from a nationally representative annual survey of US adults aged 18 and older that was conducted in person and with follow-up by phone in 2024. In 2024, for the first time, participants in the annual survey who had diabetes were asked if they were using the Lilly or Novo blockbusters or other GLP-1 drugs to lower blood sugar or lose weight. The drugs mimic the activity of a hormone that regulates blood sugar levels, slows digestion and helps people feel full for longer. Drugmakers Lilly and Novo have faced criticism about the cost of the treatments, which carry a list price of about $1,000 for a month's supply. Roughly 31 percent of survey participants who reported using insulin also reported using GLP-1 drugs, as did about 28 percent of patients who were using oral drugs to control their blood sugar, according to the report, indicating that these treatments are being integrated into combination regimens. Hispanic adults with diabetes had the highest rate of GLP-1 use, at 31.3 percent, followed by Black non-Hispanic and White non-Hispanic adults, at 26.5 percent and 26.2 percent, respectively, the survey found. Only 12.1 percent of Asian non-Hispanic adults with diabetes used the drugs, which may reflect disparities in access or adoption of the therapies.


Arab News
a day ago
- Arab News
Study reveals genetic insights about Saudi and Japanese populations
RIYADH: A new study using Saudi and Japanese pangenome samples exclusively has revealed genetic insights relating to these two populations. 'Up to 12 percent of patients with genetic disorders go undiagnosed due to reliance on reference genomes that don't reflect their population's genetic background,' said Malak Abedalthagafi, professor at Tufts Medical Center and one of the lead authors of the study. 'By constructing population-specific pangenome graphs, we improve variant calling and help close this diagnostic gap.' The pangenome is considered a powerful reference tool to study individual and group DNA. Similar to how a map shows a person's position in relation to their landscape, the pangenome allows researchers to compare a person's genetic makeup with the full spectrum of genetic variation found across a population. 'Having worked on the Saudi genome for several years, contributing to this project marks a meaningful step in my commitment to advancing representation in genomics and ensuring precision medicine serves diverse populations,' Abedalthagafi said. Fellow author of the study and KAUST Professor Robert Hoehndorf explained that building the graphs, which the study calls JaSaPaGe (Japanese Saudi PanGenome), using samples from two distinctive populations offers new health insights. 'Japan and Saudi Arabia are pretty much at the opposite ends of Asia and have been separated for a long time. It gave us a chance to study the effects of population-specific pangenome graphs on variant calling when populations do not match,' Hoehndorf said. JIHS' Yosuke Kawai, another author of the study, added that there were clinical benefits to be gained for both populations. He said: 'The joint development of a population-specific pangenome graph for the Japanese and Saudi Arabian populations addresses a critical gap in global genomic representation. 'By integrating diverse data from both countries, we have created a powerful resource that not only improves variant detection accuracy but also holds great potential for advancing precision medicine tailored to each population's unique genetic landscape.' The first human pangenome was reported in 2023, but none of the DNA samples collected were taken from individuals with Arab or Japanese descent, meaning it was constructed without representation from almost 10 percent of the world's population. The study was carried out by King Abdullah University of Science and Technology, Tufts University and the Japan Institute for Health Security.